DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,504 filers reported holding DANAHER CORPORATION in Q4 2019. The put-call ratio across all filers is 1.66 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $407,000 | -26.1% | 1,574 | -27.6% | 0.04% | -22.4% |
Q2 2022 | $551,000 | +36.0% | 2,173 | +57.3% | 0.05% | +69.0% |
Q1 2022 | $405,000 | -26.8% | 1,381 | -23.9% | 0.03% | -34.1% |
Q4 2021 | $553,000 | 0.0% | 1,815 | 0.0% | 0.04% | -13.7% |
Q3 2021 | $553,000 | +14.0% | 1,815 | +0.6% | 0.05% | +41.7% |
Q2 2021 | $485,000 | +38.6% | 1,805 | +16.2% | 0.04% | +20.0% |
Q1 2021 | $350,000 | +6.7% | 1,553 | +5.1% | 0.03% | 0.0% |
Q4 2020 | $328,000 | +9.7% | 1,477 | +6.3% | 0.03% | -3.2% |
Q3 2020 | $299,000 | +20.6% | 1,390 | -0.8% | 0.03% | +10.7% |
Q2 2020 | $248,000 | +24.0% | 1,401 | +7.4% | 0.03% | +16.7% |
Q4 2019 | $200,000 | -10.7% | 1,304 | -16.0% | 0.02% | -17.2% |
Q3 2019 | $224,000 | +1.8% | 1,553 | +0.9% | 0.03% | -6.5% |
Q2 2019 | $220,000 | +8.4% | 1,539 | +0.2% | 0.03% | +6.9% |
Q1 2019 | $203,000 | -0.5% | 1,536 | -36.6% | 0.03% | -38.3% |
Q2 2017 | $204,000 | -2.9% | 2,421 | -1.3% | 0.05% | -2.1% |
Q1 2017 | $210,000 | -38.4% | 2,452 | -27.3% | 0.05% | -36.8% |
Q2 2016 | $341,000 | -9.5% | 3,371 | -15.2% | 0.08% | -8.4% |
Q1 2016 | $377,000 | -15.1% | 3,973 | -16.8% | 0.08% | -5.7% |
Q4 2015 | $444,000 | +28.7% | 4,778 | +18.2% | 0.09% | +15.8% |
Q3 2015 | $345,000 | – | 4,044 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 149,732 | $49,263,000 | 15.79% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 257,846 | $84,834,000 | 15.76% |
Riverstone Advisors, LLC | 64,448 | $21,204,000 | 9.33% |
Eos Focused Equity Management, L.P. | 34,026 | $11,195,000 | 8.72% |
Mirova US LLC | 1,152,609 | $379,219,000 | 7.12% |
Lincoln Capital LLC | 83,275 | $27,398,000 | 6.78% |
CORTLAND ASSOCIATES INC/MO | 197,469 | $64,969,000 | 6.75% |
Third Point | 2,900,000 | $954,129,000 | 6.66% |
Front Street Capital Management, Inc. | 117,523 | $36,073,000 | 6.65% |
Alphinity Investment Management Pty Ltd | 865,427 | $284,734,000 | 6.40% |